Overexpression of LAPTM4B-35 in Cervical Carcinoma

Meng, Fanling; Luo, Chen; Hu, Yuanlong; Yin, Mingzhu; Lin, Ming Tseh; Lou, Ge; Zhou, Ruanbao

doi:10.1097/pgp.0b013e3181e0898e

Cited by 25 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LAPTM4B is closely related with the biological behaviors of malignant tumors. An increase in LAPTM4B expression, as measured by mRNA and protein, was associated with tumor progression and poorer survival in patients with breast (25), pancreatic (8), colon (26), ovary (27) and cervical cancer (11). Furthermore, extensive studies have been performed to account for such outcomes.…”

Section: Discussionmentioning

confidence: 99%

“…According to BLAST program analysis, it is located in chromosomes 8q22 and is composed of seven exons separated by six introns (6,7). It was previously reported that LAPTM4B protein was markedly overexpressed in various malignant tumors, including pancreatic (8), gallbladder (9), ovarian (10) and cervical cancer (11). Two alleles of the LAPTM4B gene have been recognized, designated as LAPTM4B*1 and LAPTM4B*2 (GenBank nos.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

LAPTM4B polymorphism is associated with non-small cell lung cancer susceptibility and prognosis

et al. 2014

View full text Add to dashboard Cite

Abstract. Lysosome-associated protein transmembrane-4β (LAPTM4B) is a novel cancer-related gene that is upregulated in many tumors, and which plays important roles in carcinogenesis. It has two alleles, LAPTM4B*1 and LAPTM4B*2. LAPTM4B*1 contains only one copy of a 19-bp sequence in the first exon, whereas LAPTM4B*2 contains two tight tandem segments. Previous studies have shown that LAPTM4B*2 is a risk factor for susceptibility and prognosis of many tumors. The present study investigated the relationship between LAPTM4B polymorphism and non-small cell lung cancer (NSCLC) susceptibility and prognosis. We identified LAPTM4B genotypes with polymerase chain reaction (PCR) in peripheral blood samples. In the adjusted multivariate logistic regression analysis, we found that LAPTM4B*1/2, LAPTM4B*2/2 exhibited 1.48-fold [95% confidence interval (CI), 1.076-2.037] and 2.855-fold (95%CI, 1.722-4.734) increases in the risk of developing NSCLC compared with non-LAPTM4B*2 carriers. Furthermore, our results showed that overall survival time and disease-free survival time of patients with LAPTM4B*2 were significantly shorter than in patients carrying LAPTM4B*1 (P=0.001 and P=0.001, respectively). In addition, multivariate Cox regression analysis revealed that LAPTM4B*2 was also an independent prognostic factor for NSCLC. These results suggest that LAPTM4B polymorphisms may be a prospective marker for evaluating the risk and prognosis of NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

LAPTM4B polymorphism is associated with non-small cell lung cancer susceptibility and prognosis

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The primary anti-LAPTM4B rabbit monoclonal antibody (Bioss Inc., China) was used at a dilution of dilution 1: 200. Primary antibody was replaced with the phosphate-buffered saline as a negative staining control, and the cervical cancer with positive LAPTM4B expression was considered as a positive control [11]. …”

Section: Methodsmentioning

confidence: 99%

LAPTM4B Predicts Axillary Lymph Node Metastasis in Breast Cancer and Promotes Breast Cancer Cell Aggressiveness in Vitro

Xiao¹,

Yang²,

Meng³

et al. 2017

Cell Physiol Biochem

Self Cite

View full text Add to dashboard Cite

Purpose: Lysosome-associated protein transmembrane-4 beta (LAPTM4B) is associated with the prognosis of several human malignancies. In this study, the role of LAPTM4B in the metastatic potential of breast cancer (BC) and its underlying molecular mechanisms were investigated. Methods: The relationship between LAPTM4B expression and axillary lymph node metastasis was determined in 291 BC specimens by immunohistochemistry. The expression of LAPTM4B in paired BC cells was overexpressed and inhibited to analyse the role of LAPTM4B in the aggressiveness of BC. Cell proliferation, migration and invasion were assessed in vitro. Metastasis-related protein levels were detected through Western blot. Results: Immunohistochemical staining demonstrated that high expression level of LAPTM4B was independently associated with axillary lymph node metastasis (odds ratio=2.428; 95%CI=1.333- 4.425; P=0.004). The LAPTM4B inhibition in MCF-7 cells inhibited cell proliferation, migration, invasion, and resulted in simultaneous downregulation of phosphorylated N-cadherin, vimentin, and upregulation of E-cadherin. By contrast, the LAPTM4B overexpression promoted cell proliferation, migration, invasion, and led to simultaneous upregulation of N-cadherin, vimentin, and downregulation of E-cadherin in T47D cells. Conclusions: High expression level of LAPTM4B predicts tumor metastatic potential in patients with BC. Our results provide the first evidence of the role of LAPTM4B as an Epithelial-mesenchymal transition (EMT) inducer that promotes aggressiveness in BC cells.

show abstract

“…It could promote the proliferation of tumor cells, boost invasion and metastasis, resist apoptosis, initiate autophagy and assist drug resistance [4]. In addition, overexpression of LAPTM4B was significantly correlated with poor prognosis in breast cancer [5], gallbladder cancer [6,7], ovarian cancer [8], HCC [9][10][11], gastric cancer [12] and cervical cancer [13] LAPTM4B gene has two alleles named LAPTM4B*1 and LAPTM4B*2 (GenBank numbers AY219176 and AY219177, respectively). Allele *1 contains only one copy of a 19-bp sequence at the 5'UTR in the first exon, whereas the sequence in allele *2 is duplicated and tandemly repeated [14].…”

Section: Introductionmentioning

confidence: 99%

The Transcription Factor AP4 Promotes Oncogenic Phenotypes and Cisplatin Resistance by Regulating LAPTM4B Expression

Wang

Yue

et al. 2018

Molecular Cancer Research

View full text Add to dashboard Cite

Lysosomal-associated protein transmembrane-4 beta (LAPTM4B) is a novel oncogene, whose overexpression is involved in cancer occurrence and progression.However, the mechanism of LAPTM4B transcriptional regulation remains unclear. In this study, the results of transcription factor (TF) profiling plate arrays indicated that AP4 was a potential transcription factor regulating LAPTM4B expression. LAPTM4B was positively correlated with AP4 and they were both associated with poor overall and disease-free survival. Luciferase and EMSA assays confirmed that AP4 directly bound to the polymorphism region of LAPTM4B promoter and modulated its transcription. Functionally, AP4 promoted cell proliferation, migration, invasion and assisted drug resistance in part through up-regulation of LAPTM4B. Taken together, Implications: This study demonstrates that AP4 promotes cell growth, migration, invasion and cisplatin resistance through up-regulation of LAPTM4B expression, thus representing an attractive therapeutic target for breast cancer.

show abstract

Overexpression of LAPTM4B-35 in Cervical Carcinoma

Cited by 25 publications

References 15 publications

LAPTM4B polymorphism is associated with non-small cell lung cancer susceptibility and prognosis

LAPTM4B polymorphism is associated with non-small cell lung cancer susceptibility and prognosis

LAPTM4B Predicts Axillary Lymph Node Metastasis in Breast Cancer and Promotes Breast Cancer Cell Aggressiveness in Vitro

The Transcription Factor AP4 Promotes Oncogenic Phenotypes and Cisplatin Resistance by Regulating LAPTM4B Expression

Contact Info

Product

Resources

About